Equity ETFs Very High Risk Fund Manager: Jitendra Tolani
Equity ETFs Very High Risk
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| ETFs | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -3.22% | -1.88% | -0.34% | -0.28% | 8.54% | 8.93% | 21.53% | 13.12% | 0% | 0% | 9.96% |
| Category returns | 3.81% | -5.06% | -3.46% | -2.43% | 9.92% | 4.04% | 15.12% | 11.18% | 13.36% | 13.36% | N/A |
| Absolute returns | -3.22% | -1.88% | -0.34% | -0.28% | 8.54% | 18.67% | 79.58% | 63.79% | 0% | 0% | 57.34% |
| Rank within category | 237 | 53 | 32 | 38 | 78 | 15 | 23 | 22 | 74 | 38 | N/A |
| Total Schemes in Category | 237 | 228 | 207 | 195 | 178 | 143 | 123 | 96 | 73 | 37 | N/A |
| ETFs | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -10.86% | 34.44% | 39.59% | -2.46% | -2.59% |
| Q1 returns | N/A | -4.27% | -4.37% | 13.01% | -9.56% | -2% |
| Q2 returns | N/A | -10.46% | 14.53% | 3.84% | 4.34% | -0.6% |
| Q3 Returns | N/A | 7.1% | 12.5% | 18.32% | -2.37% | N/A |
| Q4 Returns | -1.68% | -2.9% | 9.11% | 0.53% | 5.88% | N/A |
Expense ratio: 0.21%
Inclusive of GST
Exit load
| Alpha | -0.0151962 |
| Beta | 0.9988 |
| Sharpe Ratio | 0.330647 |
| Sortino Ratio | 0.749511 |
| R-Squared | 0.9971 |
| Tracking Error | 0.055 |
| Downside Risk | 16.5875 |
| Std. Deviation (Annualised) | 14.6981 |
| ETFs | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPSE Exchange Traded Scheme | 0.84% | 10.74% | 11.14% | 10.84% | 20.12% | 36.26% | 36.19% | 18.04% | 15.92% | 20,592.20 | 0.07 | 0.40 | Very High |
| Motilal Oswal BSE Enhanced Value ETF | 0.86% | -1.8% | 5.97% | 9.13% | 23.43% | 32.64% | 0% | 0% | 32.91% | 146.76 | 0.35 | 0.36 | Very High |
| ICICI Prudential Nifty PSU Bank ETF | 2.29% | -0.16% | 12.82% | 23.76% | 41.54% | 32.22% | 0% | 0% | 33.17% | 110.26 | 0.40 | 0.30 | Very High |
| Kotak Nifty PSU Bank ETF | 2.28% | -0.19% | 12.75% | 23.65% | 41.38% | 32.02% | 33.68% | 13.53% | 6.81% | 2,148.17 | 0.49 | 0.30 | Very High |
| Nippon India ETF Nifty PSU Bank BeES | 2.27% | -0.19% | 12.75% | 23.66% | 41.38% | 32% | 33.71% | 13.59% | 7.39% | 3,670.36 | 0.49 | 0.30 | Very High |
| ICICI Prudential Nifty Auto ETF | 7.84% | -6.43% | -2.2% | 11.53% | 27.96% | 27.17% | 0% | 0% | 21.66% | 162.29 | 0.20 | 0.32 | Very High |
| Nippon India Nifty Auto ETF | 7.83% | -6.45% | -2.26% | 11.47% | 27.86% | 27.09% | 0% | 0% | 22.8% | 384.16 | 0.22 | 0.32 | Very High |
| Bharat 22 ETF | 2.93% | 4.05% | 7.98% | 10.54% | 19.47% | 26.42% | 28.41% | 0% | 15.62% | 9,797.37 | 0.07 | 0.34 | Very High |
| Kotak Nifty Midcap 50 ETF | 5.14% | -4.02% | -1.74% | -0.61% | 14.99% | 23.98% | 0% | 0% | 18.08% | 166.33 | 0.05 | 0.30 | Very High |
| Nippon India Nifty Pharma ETF Current | -3.22% | -1.88% | -0.34% | -0.28% | 8.54% | 21.53% | 0% | 0% | 9.96% | 1,247.90 | 0.21 | 0.33 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 99.97% |
| Cash & Cash Equivalents and Net Assets | 0.03% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 99.97% | |
| Others | 0.03% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 22.91% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.41% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.32% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.49% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.91% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.43% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.76% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.49% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.96% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.80% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.17% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.80% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.74% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.69% |
| JB Chemicals & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.09% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.67% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.64% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.46% |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.19% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.04% |
| Triparty Repo | Cash & Cash Equivalents and Net Assets | 0.16% | |
| Cash Margin - CCIL | Cash & Cash Equivalents and Net Assets | 0.00% | |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -0.13% | |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in ETFs.
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
The scheme benchmark is the NIFTY PHARMA - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 8.54%
3-year: 21.53%
5-year: 0%
Top holdings include names such as:
The NAV is around ₹22.67 (approx.) for the Nippon India Nifty Pharma ETF.
The fund’s AUM is approximately ₹1,248 Cr.
The expense ratio for the Regular Plan is 0.21.
.
Minimum SIP starts at ₹0.
The minimum lump sum investment is ₹1000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund manager: Jitendra Tolani
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
